Wedbush Sees Nearly 30% Upside In ProNAi Therapeutics, Initiates At Outperform

By: via Benzinga
In a report published Monday, Wedbush analyst David M. Nierengarten initiated coverage of ProNAi Therapeutics Inc (NASDAQ: DNAI) with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.